An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression

Journal of Medicinal Chemistry

Volumn 49, Issue 11, 2006, Pages 3116-3135

  Becker, Oren M ^a   Dhanoa, Dale S ^b,c   Marantz, Yael ^a   Chen, Dongli ^b   Shacham, Sharon ^a   Cheruku, Srinivasa ^b   Heifetz, Alexander ^a   Mohanty, Pradyumna ^b   Fichman, Merav ^a   Sharadendu, Anurag ^b   Nudelman, Raphael ^a   Kauffman, Michael ^b   Noiman, Silvia ^a  

^a Predix Pharmaceuticals Ltd   (Israel)

^b Predix Pharmaceuticals   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; AMIDOSULFONAMIDE; BUSPIRONE; GEPIRONE; N [3 [4 (4 CYCLOHEXYLMETHANESULFONYLAMINOBUTYL)PIPERAZIN 1 YL]PHENYL]ACETAMIDE; N [3 [4 [4 (CYCLOHEXYLMETHYLSULFONAMIDO)BUTYL] 1 PIPERAZINYL]PHENYL]ACETAMIDE; POTASSIUM CHANNEL HERG; PROLACTIN; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SULFONAMIDE; SUNEPITRON; TANDOSPIRONE; UNCLASSIFIED DRUG; ZALOSPIRONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN HEK293; COMPUTER MODEL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOG; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; HEADACHE; HUMAN; HUMAN CELL; HYPERTHERMIA; NONHUMAN; PHARMACODYNAMICS; PROCESS OPTIMIZATION; PROLACTIN BLOOD LEVEL; RAT; VOLUNTEER;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; BINDING, COMPETITIVE; BIOLOGICAL AVAILABILITY; CELL LINE; CLINICAL TRIALS, PHASE I; DOGS; DRUG DESIGN; HALF-LIFE; HUMANS; MALE; MICE; MICROSOMES, LIVER; MODELS, MOLECULAR; PATCH-CLAMP TECHNIQUES; PIPERAZINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 33744832614     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0508641     Document Type: Article

References (66)

1. Page, I. H. Serotonin (5-hydroxytryptamine). Physiol. Rev. 1954, 34, 563-88.
2. Glennon, R. A. Serotonin Receptor: Clinical Implications. Neurosci. Biobehav. Rev. 1990, 14, 35-47.
3. Wilkinson, L. O.; Dourish, C. T. Serotonin Receptor Subtypes: Basic and Clinical Aspects; Peroutka, S., Ed.; John Wiley and Sons: New York, 1991; p 147.
4. 1A receptor agonists disrupt learning and performance in rats. J. M. Pharmacol. Exp. Ther. 1999, 288, 3335-347.
5. Baumgarten, H. G., Göthert, M., Eds. Serotoninergic Neurons and 5-HT Receptors in the CNS: Handbook of Experimental Pharmacology, Vol. 129; Springer-Verlag: Berlin, 1997.
6. Martin, G. R., Eglen, R. M., Hoyer, D., Hamblin, M. W., Yocca, F., Eds. Advances in Serotonin Receptor Research: Molecular Biology, Signal Transmission, and Therapeutics; Annals of the New York Academy of Sciences: New York, 1998.
7. Hoyer, D.; Hannon, J. P.; Martin, G. R. Molecular, Pharmacological and Functional Diversity of 5-HT Receptors. Pharmacol. Biochem. Behav. 2002, 71, 533-554.
8. Martin, G. R.; Eglen, R. M.; Hoyer, D.; Hamblin, M. W.; Yocca, F. The structure and signalling properties of 5-HT receptors: an endless diversity? Trends Pharmacol Sci. 1998, 19, 2-4.
9. De Vry, J.; Schreiber, R.; Glaser, T.; Traber, J. Serotonin 1A receptors in Depression and Anxiety. Stahl, S. M.; Gastpar, M.; Keppel, J. M.; Traber, J., Eds., Raven Press: New York, 1992, p 55.
10. 1A receptor agonists: recent developments and controversial issues. Psychopharmacology (Berl) 1995, 121, 1-26.
11. 1A receptor function: a link between anxiety and depression? Pharmacol. Biochem. Behav. 1998, 59, 787-92.
12. Menard, J.; Treit, D. Effects of centrally administered anxiolytic compounds in animal models of anxiety. Neurosci. Biobehav. Rev. 1999, 23, 591-613.
13. Blier, P.; Abbott, F. V. Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain. J. Psych. Neurosci. 2001, 26, 37-43.
14. Nemeroff, C. Anxiolytics: past, present and future agents. J. Clin. Psych. 2003, 64, 3-6.
15. Goldberg, H. L.; Finnerty, R. J. The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am. J. Psychiatry 1979, 136, 1184-7.
16. Bristol-Myers Squib Company. Buspar Package Insert, Revised February 2002.
17. Sramek, J. J.; Tansman, M.; Suri, A.; Hornig-Rohan, M.; Amsterdam, J. D.; Stahl, S. M.; Weisler, R. H.; Cutler, N. R. Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. J. Clin. Psychiatry 1996, 57, 287-91.
18. Delle Chiaie, R.; Pancheri, P.; Casacchia, M.; Stratta, P.; Kotzalidis, G. D.; Zibellini, M. Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study. J. Clin. Psychopharmacol. 1995, 15, 12-9.
19. Gammans, R. E.; Stringfellow, J. C.; Hvizdos, A. J.; Seidehamel, R. J.; Cohn, J. B.; Wilcox, C. S.; Fabre, L. F.; Pecknold, J. C.; Smith, W. T.; Rickels, K. Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. A meta-analysis of eight randomized, controlled studies. Neuropsychobiology 1995, 25, 193-201.
20. Landen, M.; Eriksson, E.; Agren, H.; Fahlen, T. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J. Clin. Psychopharmacol. 1999, 19, 268-71.
21. Landen, M.; Eriksson, O.; Sundblad, C.; Andersch, B.; Naessen, T.; Eriksson, E. Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo. Psychopharmacology (Berl). 2001, 155, 292-8.
22. Gammans, R. E.; Mayol, R. F.; LaBudde, J. A. Metabolism and disposition of buspirone. Am. J. Med. 1986, 80, 41-51.
23. Blier, P. The pharmacology of putative early-onset antidepressant strategies. Eur. Neuropsychopharmacol. 2003, 13, 57-66.
24. Feiger, A. D.; Heiser, J. F.; Shrivastava, R. K.; Weiss, K. J.; Smith, W. T.; Sitsen, J. M.; Gibertini, M. Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder. J. Clin. Psychiatry. 2003, 64, 243-9.
25. Stahl, S. M.; Kaiser, L.; Roeschen, J.; Keppel Hesselink, J. M.; Orazem, J. Effectiveness of ipsapirone, a 5-HT-1A partial agonist, in major depressive disorder: support for the role of 5-HT-1A receptors in the mechanism of action of serotonergic antidepressants. Int. J. Neuropsychopharmcol. 1998, 1, 11-18.
26. Masuda, Y.; Akagawa, Y.; Hishikawa, Y. Effect of serotonin IA agonist tandospirone on depression symptoms in senile patients with dementia. Hum. Psychopharmacol. 2002, 17, 191-3.
27. Barbhaiya, R. H.; Shukla, U. A.; Pfeffer, M.; Pittman, K. A.; Shrotriya, R.; Laroudie, C.; Gammans, R. E. Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses. Eur. J. Clin. Pharmacol. 1994, 46, 41-7.
28. Timmer C. J.; Sitsen J. M. Pharmacokinetic evaluation of gepirone immediate-release capsules and gepirone extended-release tablets in healthy volunteers. J. Pharm. Sci. 2003, 92, 1773-8.
29. 1A receptor and it's ligands: structure and function. Prog. Drug Res. 1999, 52, 103-65.
30. 1A receptors: Binding profiles and intrinsic activity. Pharmacol. Biochem. Behav. 1991, 40, 1041-1051.
31. 1A receptors. Curr. Med. Chem. 2002, 9, 443-469.
32. 1A serotonin agonists and antagonists. Drug. Dev. Res. 1992, 26, 251-274.
33. 1A ligand, S 15535: A series of cis- and trans-2-(arylcycloalkylamine)-1-indanols. J. Med. Chem. 2002, 44, 165-176.
34. 2A Receptor Ligand with an Anxiolytic-Like Activity. Bioorg. Med. Chem. 2002, 10, 3817-3827.
35. 1A Agonists. J. Med. Chem. 2004, 47, 4677-4683.
36. 1A Receptor Agonists and Serotonin Reuptake Inhibitors. J. Med. Chem. 2004, 47, 4684-4692.
37. 1A Receptor Agonist. J. Med. Chem. 1996, 39, 4439-4450.
38. 1A and α1 Receptors. A Comparison of CoMFA Models. J. Med. Chem. 1997, 40, 1648-1656.
39. 1A Affinity/Selectivity. J. Med. Chem. 1997, 40, 2653-2656.
40. 1A Affinity/Selectivity. J. Med. Chem. 1961, 42, 36-49.
41. 1A/D2 Antagonist Properties. J. Med. Chem. 2001, 44, 186-197.
42. 1A/α1- Adrenergic Receptor Affinity by Classical Hansch Analysis, Artificial Neural Networks, and Computational Simulation of Ligand Recognition. J. Med. Chem. 2001, 44, 198-207.
43. 1A Affinity/Selectivity. Bioorg. Med. Chem. 2004, 12, 1551-1557.
44. Lopez-Rodriguez, M. L.; Morcillo, M. J.; Fernandez, E.; Benhamu, B.; Tejada, I.; Ayala, D.; Viso, A.; Campillo, M.; Pardo, L.; Delgado, M.; Manzanares, J.; Fuentes, J. A. Synthesis and structure-activity relationships of a new model of arylpiperazines. 8. Computational simulation of ligand-receptor interaction of 5-HT(1A)R agonists with selectivity over α-1-adrenoceptors. J. Med. Chem. 2005, 48, 2548-58.
45. Becker, O. M.; Shacham, S.; Marantz, Y.; Noiman, S. Modeling the 3D structure of GPCRs: Advances and application to drug discovery. Curr. Opin. Drug Discovery Dev. 2003, 6, 3353-361.
46. Shacham, S.; Marantz, Y.; Bar-Haim, S.; Kalid, O.; Warshaviak, D.; Avisar, N.; Inbal, B.; Heifetz, A.; Fichman, M.; Topf, M.; Naor, Z.; Noiman, S.; Becker, O. M. PREDICT Modeling and in-silico screening for G-Protein coupled receptors. Proteins 2004, 57, 51-86.
47. Becker, O. M.; Marantz, Y.; Shacham, S.; Inbal, B.; Heifetz, A.; Kalid, O.; Bar-Haim, S.; Warshaviak, D.; Fichman, M.; Noiman, S. 3D G-Protein Coupled Receptors: In Silico Driven Drug Discovery. Proc. Natl. Acad. Sci. 2004, 101, 11304-11309.
48. Jacoby, E.; Fauchere, J. L.; Raimbaud, E.; Ollivier, S.; Michel, A.; Spedding, M. A Three Binding Site Hypothesis for the Interaction of Ligands with Monoamine G Protein-coupled Receptors: Implications for Combinatorial Ligand Design. Quant. Struct.-Act. Relat. 1999, 18, 561-572.
49. 1A receptor: A site-directed mutation study. FEBS Lett. 1992, 312, 259-262.
50. Shi, L.; Javitch, J. A. The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 437-467.
51. Evers A.; Klabunde T. Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the α-1A adrenergic receptor. J. Med. Chem. 2005, 48, 1088-97.
52. Viskin, S. Long QT syndromes and torsade de pointes. Lancet 1999, 354, 1625-1633.
53. Mitcheson, J. S.; Chen, J.; Lin, M.; Culberson, C.; Sanguinetti, M. C. A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 12329-12333.
54. Pearlstein, R.; Vaz, R.; Rampe, D. Understanding the Structure-Activity Relationship of the Human Ether-a-go-go-Related Gene Cardiac K(+) Channel. A Model for Bad Behavior. J. Med. Chem. 2003, 46, 2017-2022
55. + conduction and selectivity. Science 1998, 280, 69-77.
56. Borsini, F.; Lecci, A.; Volterra, G.; Meli, A. A model to measure anticipatory anxiety in mice? Psychopharmacology 1989, 98, 207-211.
57. Olivier, B.; Zethof, T.; Pattij, T.; van Boogaert, M.; van Oorschot, R.; Leahy, C.; Costing, R.; Bouwknecht, A.; Veening, J.; van der Gugten, J.; Groenink, L. Stress-induced hyperthermia and anxiety: pharmacological validation. Eur. J. Pharmacol. 2003, 463, 117-132.
58. Brooks B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.;, Karplus, M. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 1983, 4, 187-217.
59. MacKerell, A. D., Jr.; Bashford, D.; Bellott, R. L.; Dunbrack, R. L., Jr.; Evanseck, J. D.; Field, M. J.; Fischer, S.; Gao, J.; Guo, H.; Ha, S.; Joseph-McCarthy, D.; Kuchnir, L.; Kuczera, K.; Lau, F. T. K.; Mattos, C.; Michnick, S.; Ngo, T.; Nguyen, D. T.; Prodhom, B.; Reiher, W. E., III.; Roux, B.; Schlenkrich, M.; Smith, J. C.; Stote, R.; Straub, J.; Watanabe, M.; Wiorkiewicz-Kuczera, J.; Yin, D.; Karplus, M. All-Atom Empirical Potential for Molecular Modeling and Dynamics Studies of Proteins. J. Phys. Chem. B 1998, 102, 3586-3616.
60. CONCORD, Version Tripos St. Louis, MO 63144.
61. SYBYL, Version 6.8. Tripos Inc., St. Louis, MO 63144.
62. CONFORT, Tripos St. Louis, MO 63144.
63. Ewing, T. J.; Makino, S.; Skillman, A. G.; Kuntz, I. D. DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J. Comput.-Aided Mol. Des. 2001, 15, 411-428.
64. DOCK, Version 4.0. Molecular Design Institute University of California: San Francisco, CA.
65. CSCORE, Tripos St. Louis, MO 63144.
66. Maple, J. R.; Hwang, M.-J.; Stockfisch, T. P.; Dinur, U.; Waldman, M.; Ewig, C. S.; Hagler, A. T.; Derivation of class II force fields. I. Methodology and quantum force field for the alkyl functional group and alkane molecules. J. Comput. Chem. 1994, 15, 162-182.